IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
An outstanding display of #ShockwaveIVL #BTK capabilities – well done Dr. @MeuseVIR at @AtriumHealth in Charlotte,… https://t.co/WvTKR6i6ks
Be the first to hear the latest data from #ShockwaveIVL at #LINC2021! See the results of the #PAD3OS #BTK subset &… https://t.co/kqdFXh10vi
There you go! Superb #ShockwaveIVL treatment of a tight lesion in the posterior tibial by Dr. Stanley Zimmerman at… https://t.co/pdiqaT4Be2
Hear the new #DISRUPTPAD3 Observational Study results & lessons learned from #ShockwaveIVL expert Dr.… https://t.co/Jc7ifFVvd0
The results of #DISRUPTPAD3, the largest level 1 evidence in calcified #PAD, show that #ShockwaveIVL is a superior… https://t.co/OpI5W5bxgc
Gain insight on #IntravascularLithotripsy in calcified coronary lesions from Dr. @SBasavarajaiah & Dr. Alfonso Iela… https://t.co/21J8DZHJTj
There’s good prep, and then there’s superior prep. Hear the difference - the results of #DISRUPTPAD3 - from Dr. Bil… https://t.co/lZB1Q9OsL0
EU physicians, hear a thoughtful discussion on the significance of #DISRUPTCAD3, the largest & most rigorous corona… https://t.co/klTg7a92HC
New Year, New Reimbursement for Peripheral #ShockwaveIVL! CMS has introduced new coding & added sites of service fo… https://t.co/Y8kkidN4n8
Is imaging necessary or a nice-to-have for coronary #ShockwaveIVL cases? Hear from calcium experts Drs. @DrJMHill,… https://t.co/mGqf6XcMHm
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
